Shelton Capital Management Increases Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Shelton Capital Management increased its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 401.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,350 shares of the company's stock after buying an additional 69,940 shares during the period. Shelton Capital Management's holdings in Dr. Reddy's Laboratories were worth $1,379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. boosted its position in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Aikya Investment Management Ltd boosted its holdings in shares of Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after buying an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Dr. Reddy's Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Dr. Reddy's Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after acquiring an additional 2,313,987 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Dr. Reddy's Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock valued at $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. Institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

Separately, Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

Shares of RDY traded down $0.02 during trading hours on Monday, hitting $13.20. The stock had a trading volume of 840,537 shares, compared to its average volume of 2,081,001. The firm has a 50-day moving average price of $13.20 and a 200 day moving average price of $14.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of 21.02 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.